Format

Send to

Choose Destination
See comment in PubMed Commons below
Blood. 2012 Jul 12;120(2):244-6. doi: 10.1182/blood-2012-05-427443.

Pretransplant MRD: the light is yellow, not red.

Author information

1
National Cancer Institute; Fred Hutchinson Cancer Research Center.

Abstract

In the study reported in this issue of Blood by Leung et al, detectable minimal residual disease (MRD) before hematopoietic stem cell transplantation (HSCT) was found to be prognostic for outcome, but did not prevent cure for children with acute lymphoblastic leukemia (ALL) and acute myeloid leukemia (AML).

PMID:
22791775
DOI:
10.1182/blood-2012-05-427443
Free full text
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for HighWire
    Loading ...
    Support Center